PharmaShots | Incisive News in 3 Shots

Subscribe Now

UroGen

UroGen Reports the US FDA’s NDA Acceptance of Mitomycin (UGN-102) for Treating Non-Muscle Invasive Bladder Cancer

UroGen Reports the US FDA’s NDA Acceptance of Mitomycin (UGN-102) for Treating Non-Muscle Invasive Bladder Cancer

October 16, 2024

UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invas...

October 3, 2024

UroGen Initiates P-III (ENVISION) Study of UGN-102 for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Initiates P-III (ENVISION) Study of UGN-102 for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Ca...

February 4, 2022

Insights+: The US FDA New Drug Approvals in March and April 2020

Insights+: The US FDA New Drug Approvals in March and April 2020

May 15, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us